CO5690576A2 - Profarmacos de los inhibidores de bomba de protones - Google Patents

Profarmacos de los inhibidores de bomba de protones

Info

Publication number
CO5690576A2
CO5690576A2 CO05013468A CO05013468A CO5690576A2 CO 5690576 A2 CO5690576 A2 CO 5690576A2 CO 05013468 A CO05013468 A CO 05013468A CO 05013468 A CO05013468 A CO 05013468A CO 5690576 A2 CO5690576 A2 CO 5690576A2
Authority
CO
Colombia
Prior art keywords
formula
profarmacos
proton pump
pump inhibitors
group
Prior art date
Application number
CO05013468A
Other languages
English (en)
Spanish (es)
Inventor
Michael E Garst
Original Assignee
Wiston Pharmaceuticals Llc
Univ California
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wiston Pharmaceuticals Llc, Univ California, Us Dept Veterans Affairs filed Critical Wiston Pharmaceuticals Llc
Publication of CO5690576A2 publication Critical patent/CO5690576A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CO05013468A 2002-07-19 2005-02-15 Profarmacos de los inhibidores de bomba de protones CO5690576A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39745902P 2002-07-19 2002-07-19

Publications (1)

Publication Number Publication Date
CO5690576A2 true CO5690576A2 (es) 2006-10-31

Family

ID=30771064

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05013468A CO5690576A2 (es) 2002-07-19 2005-02-15 Profarmacos de los inhibidores de bomba de protones

Country Status (22)

Country Link
US (3) US6897227B2 (enExample)
EP (1) EP1556371B1 (enExample)
JP (1) JP4463103B2 (enExample)
KR (2) KR100822981B1 (enExample)
AT (1) ATE323695T1 (enExample)
AU (1) AU2003259154B2 (enExample)
BR (1) BR0312802A (enExample)
CA (1) CA2492718C (enExample)
CO (1) CO5690576A2 (enExample)
DE (1) DE60304726T2 (enExample)
DK (1) DK1556371T3 (enExample)
ES (1) ES2263028T3 (enExample)
IL (1) IL166371A0 (enExample)
MX (1) MXPA05000657A (enExample)
NO (1) NO20050801L (enExample)
NZ (1) NZ538221A (enExample)
PL (1) PL375255A1 (enExample)
PT (1) PT1556371E (enExample)
RU (1) RU2292342C2 (enExample)
TW (1) TW200502231A (enExample)
WO (1) WO2004009583A2 (enExample)
ZA (1) ZA200501116B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AU2004264401A1 (en) * 2003-07-15 2005-02-24 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
WO2005082337A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20090048302A1 (en) * 2004-03-11 2009-02-19 Allergan, Inc. Methods and compositions for the treatment of conditions related to gastric acid secretion
WO2005105786A1 (en) 2004-04-28 2005-11-10 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20070265311A1 (en) * 2006-01-10 2007-11-15 Rubino Mark P Therapeutic Salt Compositions and Methods
BRPI0711048A2 (pt) * 2006-05-09 2011-08-23 Astrazeneca Ab formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
KR20090035195A (ko) * 2007-10-05 2009-04-09 엘지전자 주식회사 플라즈마 디스플레이 장치
WO2009044976A1 (en) * 2007-10-05 2009-04-09 Lg Electronics Inc. Plasma display device
KR100895333B1 (ko) * 2007-11-01 2009-05-07 엘지전자 주식회사 플라즈마 디스플레이 패널의 구동 방법 및 그를 이용한플라즈마 디스플레이 장치
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN103702985B (zh) 2010-12-23 2016-02-17 默沙东公司 作为crth2受体调节剂的喹喔啉和氮杂喹喔啉
WO2012087872A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
CN107405338A (zh) * 2015-01-09 2017-11-28 加州大学评议会 用于治疗胃肠道感染的组合物和方法
CN108997177A (zh) * 2018-09-04 2018-12-14 邵阳学院 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US430042A (en) * 1890-06-10 Valve
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
US4758597A (en) * 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5045522A (en) * 1990-03-27 1991-09-03 Phillips Petroleum Company Absorption composition comprising zinc titanate for removal of hydrogen sulfide from fluid streams
ES2140391T3 (es) * 1990-06-20 2000-03-01 Astra Ab Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
PL181801B1 (pl) * 1994-06-10 2001-09-28 Byk Gulden Lomberg Chem Fab Podstawione aryloalkilotioalkilotiopirydyny do zwalczania bakterii Helicobacter oraz srodek leczniczy zawierajacy podstawione aryloalkilotioalkilotiopirydyny PL
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
EP1105387B1 (en) 1998-08-10 2003-01-29 Winston Pharmateuticals LLC Prodrugs of proton pump inhibitors
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
CN1141305C (zh) * 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6599167B2 (en) * 2000-09-27 2003-07-29 Glenn Waltz Game call holder and amplifying device
CA2425363A1 (en) * 2000-10-12 2003-04-10 Fumihiko Sato Benzimidazole compounds, process for producing the same and use thereof

Also Published As

Publication number Publication date
DK1556371T3 (da) 2006-08-21
DE60304726D1 (de) 2006-05-24
ES2263028T3 (es) 2006-12-01
NO20050801L (no) 2005-02-15
CA2492718A1 (en) 2004-01-29
TW200502231A (en) 2005-01-16
US6897227B2 (en) 2005-05-24
PL375255A1 (en) 2005-11-28
KR100788778B1 (ko) 2007-12-27
US20040102484A1 (en) 2004-05-27
CA2492718C (en) 2010-12-21
EP1556371B1 (en) 2006-04-19
MXPA05000657A (es) 2005-08-19
EP1556371A2 (en) 2005-07-27
HK1079207A1 (en) 2006-03-31
NZ538221A (en) 2006-11-30
ATE323695T1 (de) 2006-05-15
AU2003259154C1 (en) 2004-02-09
AU2003259154A1 (en) 2004-02-09
US20050182101A1 (en) 2005-08-18
KR100822981B1 (ko) 2008-04-16
US20050143423A1 (en) 2005-06-30
DE60304726T2 (de) 2007-08-09
JP2005536519A (ja) 2005-12-02
RU2005105564A (ru) 2005-10-10
ZA200501116B (en) 2006-11-29
PT1556371E (pt) 2006-09-29
WO2004009583A3 (en) 2004-03-18
RU2292342C2 (ru) 2007-01-27
KR20070005029A (ko) 2007-01-09
AU2003259154B2 (en) 2006-12-07
KR20050047078A (ko) 2005-05-19
BR0312802A (pt) 2005-04-19
WO2004009583A2 (en) 2004-01-29
JP4463103B2 (ja) 2010-05-12
IL166371A0 (en) 2006-01-16

Similar Documents

Publication Publication Date Title
CO5690576A2 (es) Profarmacos de los inhibidores de bomba de protones
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
CO5540280A2 (es) Derivados aromaticos de acido dicarboxilico
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
ES2017838A6 (es) Un procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales.
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
HN2003000215A (es) Nuevos derivados de glicocido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
AR049401A1 (es) Aza-biciclononanos
ES2074323T3 (es) Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
UY27338A1 (es) Nuevos derivados de ácido sulfónico
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
CO4700291A1 (es) Compuestos quimicos
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
AR046143A1 (es) Composicion farmaceutica que contiene un derivado de tiourea con solubilidad y biodisponiblidad mejoradas
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
CR20230437A (es) Nuevos derivados de tiazolopirimidinona
AR035601A1 (es) Procesos de preparacion de inhibidores del intercambiador de sodio-hidrogeno de tipo 1, inhibidores, sales de dichos compuestos, composiciones farmaceuticas y uso de los mismos en la preparación de medicamentos
ES2086442T3 (es) Derivados de fluoroetilcamptotecina.
AR002749A1 (es) Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.

Legal Events

Date Code Title Description
FC Application refused